SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
Open Access
- 8 July 2021
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 26 (27), 2100568
- https://doi.org/10.2807/1560-7917.es.2021.26.27.2100568
Abstract
We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.Keywords
This publication has 20 references indexed in Scilit:
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasmaNature, 2021
- WHO International Standard for anti-SARS-CoV-2 immunoglobulinThe Lancet, 2021
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older AdultsThe New England Journal of Medicine, 2021
- Correlates of protection against SARS-CoV-2 in rhesus macaquesNature, 2020
- Robust neutralizing antibodies to SARS-CoV-2 infection persist for monthsScience, 2020
- Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19Blood, 2020
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal modelScience, 2020
- The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfectionJournal of General Virology, 2020
- Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020Eurosurveillance, 2020